Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus – Mechanisms, Management, and Clinical Considerations. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Circulation. 2016 Jun 14;133(24):2459-502. doi: 10.1161/CIRCULATIONAHA.116.022194. PMID:27297342

 

The Development of Therapeutics for Peripheral Artery Disease: A Unique Cardiovascular Risk Population. Hiatt WR, Rogers RK. J Am Coll Cardiol. 2016 Jun 14;67(23):2729-31. doi: 10.1016/j.jacc.2016.03.583. PMID:27282893

 

Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess? Smith RJ, Goldfine AB, Hiatt WR. Diabetes Care. 2016 May;39(5):738-42. doi: 10.2337/dc15-2237. PMID:27208377

 

Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. Berger JS, Katona BG, Jones WS, Patel MR, Norgren L, Baumgartner I, Blomster J, Mahaffey KW, Held P, Millegård M, Heizer G, Reist C, Fowkes FG, Hiatt WR. Am Heart J. 2016 May;175:86-93. doi: 10.1016/j.ahj.2016.01.018. Epub 2016 Jan 28. PMID:27179727

 

Drivers of readmissions in vascular surgery patients. Glebova NO, Bronsert M, Hammermeister KE, Nehler MR, Gibula DR, Malas MB, Black JH, Henderson WG. J Vasc Surg. 2016 Mar 30. pii: S0741-5214(16)00250-0. doi: 10.1016/j.jvs.2016.02.024. [Epub ahead of print] PMID:27038838

 

Contributions of planned readmissions and patient comorbidities to high readmission rates in vascular surgery patients. Glebova NO, Bronsert M, Hicks CW, Malas MB, Hammermeister KE, Black JH 3rd, Nehler MR, Henderson WG. J Vasc Surg. 2016 Mar;63(3):746-755.e2. doi: 10.1016/j.jvs.2015.09.032. PMID:26916584

 

Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options.

Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. J Am Coll Cardiol. 2016 Mar 22;67(11):1338-57. doi: 10.1016/j.jacc.2015.12.049. PMID:26988957

 

The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4. PMID:26842902

 

Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study.

Violi F, Davì G, Proietti M, Pastori D, Hiatt WR, Corazza GR, Perticone F, Pignatelli P, Farcomeni A, Vestri AR, Lip GY, Basili S; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY Investigators. Thromb Haemost. 2016 Apr 1;115(4):856-63. doi: 10.1160/TH15-07-0612. Epub 2016 Jan 7. PMID:26740316

 

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II): The TASC Steering Committee(.). Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. Ann Vasc Dis. 2015;8(4):343-57. doi: 10.3400/avd.tasc.15-01000. Epub 2015 Oct 23. PMID:26730266

 

Reducing LDL with PCSK9 Inhibitors–The Clinical Benefit of Lipid Drugs. Everett BM, Smith RJ, Hiatt WR. N Engl J Med. 2015 Oct 22;373(17):1588-91. doi: 10.1056/NEJMp1508120. Epub 2015 Oct 7. PMID:26444323

 

Computed tomography-guided reoperation for neurogenic thoracic outlet syndrome. Greenberg JI, Alix K, Nehler MR, Johnston RJ, Brantigan CO. J Vasc Surg. 2015 Feb;61(2):469-74. doi: 10.1016/j.jvs.2014.07.008. Epub 2014 Aug 15. PMID:25135877

 

Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, Zakharyan A, Hirsch AT. J Vasc Surg. 2014 Sep;60(3):686-95.e2. doi: 10.1016/j.jvs.2014.03.290. Epub 2014 May 10. PMID:24820900

 

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators. N Engl J Med. 2015 Jul 9;373(2):145-53. doi: 10.1056/NEJMoa1406235. Epub 2015 Jun 24. PMID:26106946

 

Measures to reduce unplanned readmissions after vascular surgery. Eun JC, Nehler MR, Black JH 3rd, Glebova NO. Semin Vasc Surg. 2015 Jun;28(2):103-11. doi: 10.1053/j.semvascsurg.2015.09.002. Epub 2015 Sep 8. PMID:26655054

 

Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. Pastori D, Pignatelli P, Farcomeni A, Cangemi R, Hiatt WR, Bartimoccia S, Nocella C, Vicario T, Bucci T, Carnevale R, Lip GY, Violi F. Am Heart J. 2015 Sep;170(3):490-7.e1. doi: 10.1016/j.ahj.2015.05.011. Epub 2015 May 22. PMID:26385032

 

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. Vasc Med. 2015 Oct;20(5):465-78. doi: 10.1177/1358863X15597877. Epub 2015 Aug 12. PMID:26268268

 

An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee. Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. Catheter Cardiovasc Interv. 2015 Oct;86(4):611-25. doi: 10.1002/ccd.26122. Epub 2015 Aug 10. PMID:26256456

 

An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). TASC Steering Committee, Jaff MR, White CJ, Hiatt WR, Fowkes GR, Dormandy J, Razavi M, Reekers J, Norgren L. J Endovasc Ther. 2015 Oct;22(5):663-77. doi: 10.1177/1526602815592206. Epub 2015 Aug 3. PMID:26239796

 

Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings. Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators. J Thromb Haemost. 2015 Sep;13(9):1597-605. doi: 10.1111/jth.13038. Epub 2015 Aug 11. PMID:26118944

 

Toxicity of a novel therapeutic agent targeting mitochondrial complex I. Low Wang CC, Galinkin JL, Hiatt WR. Clin Pharmacol Ther. 2015 Nov;98(5):551-9. doi: 10.1002/cpt.178. Epub 2015 Aug 4. PMID:26108785

 

Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study. Violi F, Pastori D, Perticone F, Hiatt WR, Sciacqua A, Basili S, Proietti M, Corazza GR, Lip GY, Pignatelli P; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study) STUDY group. BMJ Open. 2015 May 21;5(5):e008026. doi: 10.1136/bmjopen-2015-008026. PMID:25998039

 

Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease. Hiatt WR, Armstrong EJ, Larson CJ, Brass EP. Circ Res. 2015 Apr 24;116(9):1527-39. doi: 10.1161/CIRCRESAHA.116.303566. PMID:25908726

 

Cardiovascular drug development: is it dead or just hibernating? Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM. J Am Coll Cardiol. 2015 Apr 21;65(15):1567-82. doi: 10.1016/j.jacc.2015.03.016. PMID:25881939

 

Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. Sager PT, Seltzer J, Turner JR, Anderson JL, Hiatt WR, Kowey P, Prochaska JJ, Stockbridge N, White WB. Am Heart J. 2015 Apr;169(4):486-95. doi: 10.1016/j.ahj.2015.01.007. Epub 2015 Jan 15. PMID:25819855

 

Community-based walking exercise for peripheral artery disease: An exploratory pilot study.

Mays RJ, Hiatt WR, Casserly IP, Rogers RK, Main DS, Kohrt WM, Ho PM, Regensteiner JG. Vasc Med. 2015 Aug;20(4):339-47. doi: 10.1177/1358863X15572725. Epub 2015 Mar 9. PMID:25755148

 

Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, Jaff MR, Jones WS, Kawahara M, Lookstein RA, Mehran R, Misra S, Norgren L, Olin JW, Povsic TJ, Rosenfield K, Rundback J, Shamoun F, Tcheng J, Tsai TT, Suzuki Y, Vranckx P, Wiechmann BN, White CJ, Yokoi H, Krucoff MW. J Am Coll Cardiol. 2015 Mar 10;65(9):931-41. doi: 10.1016/j.jacc.2014.12.036. Erratum in: J Am Coll Cardiol. 2015 Jun 16;65(23):2578-9. PMID:25744011

 

The Society for Vascular Medicine: the first quarter century. Creager MA, Hiatt WR, Hirsch AT, Olin JW, Jaff MR, Cooke JP, Rooke T, Beckman JA, Froehlich JB. Vasc Med. 2015 Feb;20(1):60-8. doi: 10.1177/1358863X14566042. PMID:25722420

 

Association between physical activity and peripheral artery disease and carotid artery stenosis in a self-referred population of 3 million adults. Stein RA, Rockman CB, Guo Y, Adelman MA, Riles T, Hiatt WR, Berger JS. Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):206-12. doi: 10.1161/ATVBAHA.114.304161. PMID:25359858

 

Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Olson E, Demopoulos L, Haws TF, Hu E, Fang Z, Mahar KM, Qin P, Lepore J, Bauer TA, Hiatt WR. Vasc Med. 2014 Dec;19(6):473-82. doi: 10.1177/1358863X14557151. PMID:25377872

 

Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells. Perin EC, Murphy M, Cooke JP, Moyé L, Henry TD, Bettencourt J, Gahremanpour A, Leeper N, Anderson RD, Hiatt WR, Lima JA, Venkatesh B, Sayre SL, Vojvodic RW, Taylor DA, Ebert RF, Hirsch AT; Cardiovascular Cell Therapy Research Network. Am Heart J. 2014 Nov;168(5):667-73. doi: 10.1016/j.ahj.2014.07.021. PMID:25440794

 

Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. Subherwal S, Patel MR, Chiswell K, Tidemann-Miller BA, Jones WS, Conte MS, White CJ, Bhatt DL, Laird JR, Hiatt WR, Tasneem A, Califf RM. Circulation. 2014 Nov 11;130(20):1812-9. doi: 10.1161/CIRCULATIONAHA.114.011021. PMID:25239436

 

Heart failure and peripheral artery disease: an unappreciated association. Hiatt WR. JACC Heart Fail. 2014 Oct;2(5):455-6. doi: 10.1016/j.jchf.2014.06.001. PMID:25194283

 

Minimal thoracotomy thoracic bifemoral bypass in the endovascular era. Reppert AE, Jazaeri O, Babu A, Greenberg JI, Deluka E, Nehler MR, Reece TB. Ann Vasc Surg. 2014 Aug;28(6):1420-5. doi: 10.1016/j.avsg.2014.03.023. PMID:24704047

 

Response to McDermott. Hiatt WR, Rogers K, Brass EP. Circulation. 2014 Jul 1;130(1):68. PMID:25110791

 

The treadmill is a better functional test than the 6-minute walk test in therapeutic trials of patients with peripheral artery disease. Hiatt WR, Rogers RK, Brass EP. Circulation. 2014 Jul 1;130(1):69-78. doi: 10.1161/CIRCULATIONAHA.113.007003. PMID:24982118

 

Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR. Vasc Med. 2014 May 28;19(4):297-306. PMID:24872402

 

Response to ‘Statement from the European Society of Vascular Surgery and the World Federation of Vascular Surgery Societies’ Inter-Society Consensus Document (TASC) III and International Standards for Vascular Care (ISVaC). Norgren L, Hiatt WR, Jaff MR. Eur J Vasc Endovasc Surg. 2014 May;47(5):461. PMID:24851281

 

Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. Patel MR, Becker RC, Wojdyla DM, Emanuelsson H, Hiatt WR, Horrow J, Husted S, Mahaffey KW, Steg PG, Storey RF, Wallentin L, James SK. Eur J Prev Cardiol. 2015 Jun;22(6):734-42. doi: 10.1177/2047487314533215. PMID:24830710

 

Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population.

Nehler MR, Duval S, Diao L, Annex BH, Hiatt WR, Rogers K, Zakharyan A, Hirsch AT. J Vasc Surg. 2014 Sep;60(3):686-95.e2. doi: 10.1016/j.jvs.2014.03.290. PMID:24820900

 

Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Fowkes FG, Murray GD, Butcher I, Folsom AR, Hirsch AT, Couper DJ, Debacker G, Kornitzer M, Newman AB, Sutton-Tyrrell KC, Cushman M, Lee AJ, Price JF, D’Agostino RB Sr, Murabito JM, Norman P, Masaki KH, Bouter LM, Heine RJ, Stehouwer CD, McDermott MM, Stoffers HE, Knottnerus JA, Ogren M, Hedblad B, Koenig W, Meisinger C, Cauley JA, Franco O, Hunink MG, Hofman A, Witteman JC, Criqui MH, Langer RD, Hiatt WR, Hamman RF; Ankle Brachial Index Collaboration. Eur J Prev Cardiol. 2014 Mar;21(3):310-20. doi: 10.1177/2047487313516564. PMID:24367001

 

Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function. Mohler ER 3rd, Hiatt WR, Gornik HL, Kevil CG, Quyyumi A, Haynes WG, Annex BH. Vasc Med. 2014 Feb;19(1):9-17. doi: 10.1177/1358863X13515043. PMID:24363302

 

 

Bridging the gap from T to K: integrated surgical research fellowship for the next generation of surgical scientists. Moore HB, Moore EE, Nehler MR, Cicutto LC, Bacon AW, Travis C, Schulick RD. J Am Coll Surg. 2014 Feb;218(2):279-82. doi: 10.1016/j.jamcollsurg.2013.10.026. Review. No abstract available. PMID:24315889

 

Assessing the clinical benefits of lipid-disorder drugs. Hiatt WR, Smith RJ. N Engl J Med. 2014 Jan 30;370(5):396-9. doi: 10.1056/NEJMp1313866. PMID:24476429

 

Community walking programs for treatment of peripheral artery disease. Mays RJ, Rogers RK, Hiatt WR, Regensteiner JG. J Vasc Surg. 2013 Dec;58(6):1678-87. doi: 10.1016/j.jvs.2013.08.034. PMID:24103409

 

The cardiovascular safety of diabetes drugs–insights from the rosiglitazone experience. Hiatt WR, Kaul S, Smith RJ. N Engl J Med. 2013 Oct 3;369(14):1285-7. doi: 10.1056/NEJMp1309610. PMID:23992603

 

Omega-3 fatty acids for intermittent claudication. Campbell A, Price J, Hiatt WR. Cochrane Database Syst Rev. 2013 Jul 4;(7):CD003833. doi: 10.1002/14651858.CD003833.pub4. PMID:23824785

 

Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt WR, Goldenberg NA; Antithrombotic Trials Leadership and Steering (ATLAS) Group. J Thromb Haemost. 2013 Aug;11(8):1443-8. doi: 10.1111/jth.12324. PMID:23773172

 

Should an alternate ABI definition be adopted to evaluate risk? Hiatt WR. J Am Coll Cardiol. 2013 Aug 6;62(6):560-1. doi: 10.1016/j.jacc.2013.04.056. PMID:23707314

 

Association of clinical attributes and treadmill walking performance in patients with claudication due to peripheral artery disease. Brass EP, Cooper LT, Hanson P, Hiatt WR.

J Vasc Surg. 2013 Aug;58(2):396-403. doi: 10.1016/j.jvs.2012.12.077. Epub 2013 May 16. PMID:23684414

 

Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. Cangemi R, Pignatelli P, Carnevale R, Corazza GR, Pastori D, Farcomeni A, Basili S, Davì G, Ferro D, Hiatt WR, Licata G, Lip GY, Loffredo L, Mannucci PM, Vestri A, Violi F; ARA PACIS study group. Int J Cardiol. 2013 Oct 9;168(4):3241-7. doi: 10.1016/j.ijcard.2013.04.142. Epub 2013 May 5. PMID:23651827

 

Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. Smith RJ, Hiatt WR. JAMA Intern Med. 2013 Sep 9;173(16):1491-2. doi: 10.1001/jamainternmed.2013.6624. PMID:23649296

 

Vascular disease: vorapaxar prevents progression of peripheral artery disease.

Hiatt WR. Nat Rev Cardiol. 2013 Jul;10(7):367-8. doi: 10.1038/nrcardio.2013.66. Epub 2013 Apr 30. PMID:23629438

 

Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia. Misra S, Lookstein R, Rundback J, Hirsch AT, Hiatt WR, Jaff MR, White CR, Conte M, Geraghty P, Patel M, Rosenfield K. J Vasc Interv Radiol. 2013 Apr;24(4):451-8. doi: 10.1016/j.jvir.2012.10.028. PMID:23522155

 

A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication. Brass EP, Koster D, Hiatt WR, Amato A. Vasc Med. 2013 Feb;18(1):3-12. doi: 10.1177/1358863X12467491. PMID:23321261

 

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK. Endocr Pract. 2013 Jan-Feb;19(1):19-28. doi: 10.4158/EP12100.OR. PMID:23186950

 

Prevalence of Peripheral Artery Disease by Abnormal Ankle-Brachial Index in Atrial Fibrillation: Implications for Risk and Therapy. Violi F, Davi G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S. J Am Coll Cardiol 2013;62:2255-6. PMID:23954332

 

 

Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, Fowkes FG, Hiatt WR, Jönsson B, Lacroix P, Marin B, McDermott MM, Norgren L, Pande RL, Preux PM, Stoffers HE, Treat-Jacobson D; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Circulation. 2012 Dec 11;126(24):2890-909. doi: 10.1161/CIR.0b013e318276fbcb. Erratum in: Circulation. 2013 Jan 1;127(1):e264. PMID:23159553

 

Selection, mentorship, and subsequent placement of preliminary residents without a designated categorical position in an academic general surgery residency program. Montero P, Powell R, Travis CM, Nehler MR. J Surg Educ. 2012 Nov-Dec;69(6):785-91. doi: 10.1016/j.jsurg.2012.04.009. PMID:23111047

 

A validated biomarker panel to identify peripheral artery disease. Hiatt WR, Zakharyan A, Fung ET, Crutcher G, Smith A, Stanford C, Cooke J. Vasc Med. 2012 Dec;17(6):386-93. doi: 10.1177/1358863X12463491. PMID:23086582

 

Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AG, Cutler NR, Hiatt WR, Halperin JL; Antithrombotic Trials Leadership and Steering Group (ATLAS). J Thromb Haemost. 2012 Dec;10(12):2621-4. doi: 10.1111/jth.12005. PMID:23006126

 

Cardiovascular risk assessment in the development of new drugs for obesity. Hiatt WR, Goldfine AB, Kaul S. JAMA. 2012 Sep 19;308(11):1099-100. PMID:22990267

 

Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. Subherwal S, Anstrom KJ, Jones WS, Felker MG, Misra S, Conte MS, Hiatt WR, Patel MR. Am Heart J. 2012 Sep;164(3):277-84. doi: 10.1016/j.ahj.2012.07.002. PMID:22980292

 

Antiplatelet therapy in peripheral artery disease. Violi F, Basili S, Berger JS, Hiatt WR. Handb Exp Pharmacol. 2012;(210):547-63. doi: 10.1007/978-3-642-29423-5_22. PMID:22918746

 

Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting. Kao DP, Hiatt WR, Krantz MJ. Pharmacotherapy. 2012 Aug;32(8):767-71. doi: 10.1002/j.1875-9114.2012.01118.x. PMID: 22744806

 

Improving the FDA’s advisory committee process. Brass EP, Hiatt WR. J Clin Pharmacol. 2012 Aug;52(8):1277-83. doi: 10.1177/0091270011412962. PMID:21908879

 

Medical therapy in peripheral artery disease. Berger JS, Hiatt WR.

Circulation. 2012 Jul 24;126(4):491-500. doi: 10.1161/CIRCULATIONAHA.111.033886. PMID:22825411

 

Aspirin in primary prevention: can we individualize care? Lala A, Hiatt WR, Berger JS. Cardiovasc Diagn Ther. 2012 Jun;2(2):169-72. doi: 10.3978/j.issn.2223-3652.2012.04.02. PMID:24282710

 

L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial. Goldenberg NA, Krantz MJ, Hiatt WR. Vasc Med. 2012 Jun;17(3):145-54. doi: 10.1177/1358863X12442264. PMID:22615190

 

Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. Jones WS, Duscha BD, Robbins JL, Duggan NN, Regensteiner JG, Kraus WE, Hiatt WR, Dokun AO, Annex BH. Vasc Med. 2012 Apr;17(2):94-100. doi: 10.1177/1358863X11436334. PMID:22402934

 

A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Hirsch AT, Allison MA, Gomes AS, Corriere MA, Duval S, Ershow AG, Hiatt WR, Karas RH, Lovell MB, McDermott MM, Mendes DM, Nussmeier NA, Treat-Jacobson D; American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; Council on Epidemiology and Prevention. Circulation. 2012 Mar 20;125(11):1449-72. doi: 10.1161/CIR.0b013e31824c39ba. PMID:22343782

 

What cost weight loss? Hiatt WR, Thomas A, Goldfine AB. Circulation. 2012 Mar 6;125(9):1171-7. doi: 10.1161/CIRCULATIONAHA.111.023499. PMID:22392864

 

Progression of asymptomatic peripheral artery disease over 1 year. Mohler ER 3rd, Bundens W, Denenberg J, Medenilla E, Hiatt WR, Criqui MH. Vasc Med. 2012 Feb;17(1):10-6. doi: 10.1177/1358863X11431106. PMID: 22363014

 

A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Brass EP, Cooper LT, Morgan RE, Hiatt WR. J Vasc Surg. 2012 Feb;55(2):381-389.e1. doi: 10.1016/j.jvs.2011.09.004. PMID:22119244

 

The computerized rounding report: implementation of a model system to support transitions of care. Wohlauer MV, Rove KO, Pshak TJ, Raeburn CD, Moore EE, Chenoweth C, Srivastava A, Pell J, Meacham RB, Nehler MR. J Surg Res. 2012 Jan;172(1):11-7. doi: 10.1016/j.jss.2011.04.015. PMID:21777923

 

Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. Duscha BD, Robbins JL, Jones WS, Kraus WE, Lye RJ, Sanders JM, Allen JD, Regensteiner JG, Hiatt WR, Annex BH. Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2742-8. doi: 10.1161/ATVBAHA.111.230441. PMID:21868709

 

Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication. Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR. Circulation. 2011 Oct 18;124(16):1765-73. doi: 10.1161/CIRCULATIONAHA.110.009407. PMID:21947297

 

Efficiency of the kidney disease outcomes quality initiative guidelines for preemptive vascular access in an academic setting. Kimball TA, Barz K, Dimond KR, Edwards JM, Nehler MR.

J Vasc Surg. 2011 Sep;54(3):760-5; discussion 765-6. doi: 10.1016/j.jvs.2011.03.006. PMID:21703804

 

Commentary. The fate of the claudicant–a prospective study of 1969 claudicants. Hiatt WR. Eur J Vasc Endovasc Surg. 2011 Sep;42 Suppl 1:S7-8. doi: 10.1016/j.ejvs.2011.06.035. PMID:21855027

 

Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia. Van Belle E, Nikol S, Norgren L, Baumgartner I, Driver V, Hiatt WR, Belch J. Eur J Vasc Endovasc Surg. 2011 Sep;42(3):365-73. doi: 10.1016/j.ejvs.2011.04.030. PMID:21696982

 

Fibrates in the treatment of dyslipidemias–time for a reassessment. Goldfine AB, Kaul S, Hiatt WR. N Engl J Med. 2011 Aug 11;365(6):481-4. doi: 10.1056/NEJMp1106688. PMID:21830963

 

Prevalence of abnormal ankle-brachial index among individuals with low or intermediate Framingham Risk Scores. Dhangana R, Murphy TP, Coll JR, Ahn SH, Zafar AM, Qadeer FF, Hiatt WR. J Vasc Interv Radiol. 2011 Aug;22(8):1077-82. doi: 10.1016/j.jvir.2011.04.008. PMID:21705232

 

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR.

Am Heart J. 2011 Jul;162(1):115-24.e2. doi: 10.1016/j.ahj.2011.04.006. PMID:21742097

 

Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. Robbins JL, Jones WS, Duscha BD, Allen JD, Kraus WE, Regensteiner JG, Hiatt WR, Annex BH. J Appl Physiol (1985). 2011 Jul;111(1):81-6. doi: 10.1152/japplphysiol.00141.2011. PMID:21512146

 

Chinese translation and validation of the Walking Impairment Questionnaire in patients with peripheral artery disease. Yan BP, Lau JY, Yu CM, Au K, Chan KW, Yu DS, Ma RC, Lam YY, Hiatt WR. Vasc Med. 2011 Jun;16(3):167-72. doi: 10.1177/1358863X11404934. PMID:21636675

 

Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E; TAMARIS Committees and Investigators. Lancet. 2011 Jun 4;377(9781):1929-37. doi: 10.1016/S0140-6736(11)60394-2. PMID:21621834

 

Assessment of functional status and quality of life in claudication. Mays RJ, Casserly IP, Kohrt WM, Ho PM, Hiatt WR, Nehler MR, Regensteiner JG. J Vasc Surg. 2011 May;53(5):1410-21. doi: 10.1016/j.jvs.2010.11.092. PMID:21334172

 

Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Lewis RJ, Connor JT, Teerlink JR, Murphy JR, Cooper LT, Hiatt WR, Brass EP. Trials. 2011 May 25;12:134. doi: 10.1186/1745-6215-12-134. PMID:21612611

 

Assessment of functional status and quality of life in claudication. Mays RJ, Casserly IP, Kohrt WM, Ho PM, Hiatt WR, Nehler MR, Regensteiner JG. J Vasc Surg. 2011 May;53(5):1410-21. doi: 10.1016/j.jvs.2010.11.092. PMID:21334172

 

Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery disease. Hiatt WR, Creager MA, Amato A, Brass EP.

J Cardiopulm Rehabil Prev. 2011 Mar-Apr;31(2):125-32. doi: 10.1097/HCR.0b013e3181f1fd65.

PMID:20861750

 

Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model. Goldenberg NA, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Turpie AG, Skene AM, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering Group. Blood. 2011 Feb 17;117(7):2089-92. doi: 10.1182/blood-2010-09-308858. PMID:21068436